Dietary fatty acids have a profound impact on atherosclerosis, but mechanisms are not fully understood. We studied the effects of a saturated fat diet supplemented with fish oil, trans10,cis12 conjugated linoleic acid (CLA), or elaidic acid on lipid and glucose metabolism and liver protein levels of APOE*3 Leiden transgenic mice, a model for lipid metabolism and atherosclerosis. Fish oil lowered plasma and liver cholesterol and triglycerides, plasma free fatty acids, and glucose but increased plasma insulin. CLA lowered plasma cholesterol but increased plasma and liver triglycerides, plasma β-hydroxybutyrate, and insulin. Elaidic acid lowered plasma and liver cholesterol. Proteomics identified significant regulation of 65 cytosolic and 8-membrane proteins. Many of these proteins were related to lipid and glucose metabolism, and to oxidative stress. Principal component analysis revealed that fish oil had a major impact on cytosolic proteins, and elaidic acid on membrane proteins. Correlation analysis between physiological and protein data revealed novel clusters of correlated variables, among which a metabolic syndrome cluster. The combination of proteomics and physiology gave new insights in mechanisms by which these dietary fatty acids regulate lipid metabolism and related pathways, for example, by altering protein levels of long-chain acyl-CoA thioester hydrolase and adipophilin in the liver. oronary heart disease (CHD) is one of the major causes of mortality in industrialized countries, with diet believed to play a major role in disease development. Several dietary fatty acids may contribute to, or decrease the risk of CHD, primarily because of their detrimental, or beneficial, effects on the lipoprotein profile (1). Numerous controlled feeding studies in humans have established that saturated fatty acids increase and polyunsaturated fatty acids decrease total and low-density lipoprotein (LDL) cholesterol (2). Trans fatty acids have been shown to raise LDL cholesterol and lower high-density lipoprotein (HDL) cholesterol relative to cis-unsaturated fatty acids (3, 4) and increase triglycerides (5). Conjugated linoleic acids (CLA), which structurally may be classed as trans fatty acids, protect against the development of atherosclerosis in rabbits, hamsters, and transgenic mice (6) (7) (8) . Nevertheless, in vivo data on possible hypolipidemic effects of CLA are conflicting (9).
oronary heart disease (CHD) is one of the major causes of mortality in industrialized countries, with diet believed to play a major role in disease development. Several dietary fatty acids may contribute to, or decrease the risk of CHD, primarily because of their detrimental, or beneficial, effects on the lipoprotein profile (1) . Numerous controlled feeding studies in humans have established that saturated fatty acids increase and polyunsaturated fatty acids decrease total and low-density lipoprotein (LDL) cholesterol (2) . Trans fatty acids have been shown to raise LDL cholesterol and lower high-density lipoprotein (HDL) cholesterol relative to cis-unsaturated fatty acids (3, 4) and increase triglycerides (5) . Conjugated linoleic acids (CLA), which structurally may be classed as trans fatty acids, protect against the development of atherosclerosis in rabbits, hamsters, and transgenic mice (6) (7) (8) . Nevertheless, in vivo data on possible hypolipidemic effects of CLA are conflicting (9) .
The mechanisms by which the different dietary fatty acids affect lipid metabolism and the development of CHD are not completely understood, although some studies are available. Omega-3 fatty acids (present in fish and fish oil) decrease triglyceride levels by inhibition of fatty acid synthesis in the liver and up-regulation of mitochondrial and peroxisomal fatty acid oxidation in liver and skeletal muscle (10) . The effects of CLA on lipid metabolism appear to be produced largely by the trans10,cis12 isomer of CLA. This isomer significantly suppressed apolipoprotein B secretion from HepG2 cells (11) as well as hepatic stearoyl-CoA desaturase expression (12) and activity (13) . Although these results suggest a triglyceride-lowering effect of t10,c12 CLA mediated by falls in VLDL triglyceride secretion and fatty acid synthesis, respectively, in vivo data on the hypolipidemic effects of CLA are inconsistent (9) . Trans-fatty acids adversely affect essential fatty acid metabolism and prostaglandin balance by inhibiting the enzyme delta-6 desaturase (14) , and they may promote insulin resistance (15) .
The differences in study design and the conflicting results from different animal models make it difficult to assess the physiological, biochemical, and molecular mechanisms by which these dietary fatty acids exert their effect. Thus, studies are needed in which the effects of different dietary fatty acids are studied in a single model that is sensitive to relatively mild perturbations in the diet. The apolipoprotein E*3-Leiden (APOE*3-Leiden) mouse model responds well to modulators of lipoprotein metabolism and atherosclerosis, such as cafestol and plant stanols (16) (17) (18) . In addition, APOE*3-Leiden mice have proven responsive to fish oil (19) . APOE*3-Leiden mice express the human APOE*3-Leiden gene, causing an impaired clearance of remnant lipoproteins from plasma, resulting in a lipoprotein profile similar to that of humans. Hence, these mice easily develop diet-induced hyperlipidemia and atherosclerosis (20, 21) and are therefore suitable for a comparative study on the effects of dietary fatty acids.
In this study, we have compared the impact of dietary fish oil, t10,c12 CLA, and elaidic acid on lipoprotein metabolism and insulin levels. Both CLA and fish oil are suggested to act as peroxisome proliferator-activated receptor (PPAR) agonists (10, 22) , and therefore we also included the triglyceride-lowering drug fenofibrate as a positive control. Fibrates are PPAR agonists known to stimulate cellular fatty acid uptake, conversion of fatty acids to acyl-CoA derivatives, and catabolism of fatty acids via the β-oxidation pathways. Combined with a reduction in fatty acid and triglyceride synthesis, this results in a decrease in very-low-density lipoprotein (VLDL) production (23) , an observation confirmed in the APOE*3-Leiden mouse. Effects on fatty acid, lipoprotein, and glucose metabolism were assessed by measuring metabolite concentrations in plasma. Impact on liver physiology was studied by liver lipid C analysis and by 2-dimensional gel electrophoresis on both cytosolic and membrane proteins. Proteomics was used to identify potential pathways through which dietary fatty acids may exert their specific effects on physiology and CHD.
MATERIALS AND METHODS
This study was approved by the animal care committee of TNO Prevention and Health, Leiden, the Netherlands.
Animals and diet
Female APOE*3-Leiden transgenic mice, aged 5-6 months, were kept in groups of 4 under standard conditions with free access to food and water. Forty animals consumed a semi-synthetic high-fat/cholesterol (HFC) diet (Hope Farms, The Netherlands) containing cocoa butter (15% w/w) and cholesterol (0.25% w/w) during a 3-week run-in period. They were then randomly assigned to 5 treatment groups of 8 animals each that were matched for body weight and total cholesterol. During the intervention period of 3 weeks, one group continued to be given the HFC diet (control group). The second group (fish oil group) received the HFC diet supplemented with 3% (w/w) of fish oil containing a mixture of EPA and DHA (Marinol TM , Loders Croklaan, The Netherlands). The third group (CLA group) received the HFC diet supplemented with 1% (w/w) of the t10,c12 isomer of CLA (Loders Croklaan, The Netherlands). The fourth group (elaidic acid group) received the HFC diet supplemented with 3% (w/w) of elaidic acid (Loders Croklaan, The Netherlands). The fifth group (fenofibrate group) received the HFC diet supplemented with 0.04% (w/w) of fenofibrate (Sigma, Dorset, UK). All supplements were added at the expense of cocoa butter, leading to equal fat and energy contents per gram food in the different diets ( Table 1 ). The percentage of energy provided by fish oil (EPA+DHA), t10,c12 CLA, and elaidic acid was 2.3, 1.7, and 4.1%, respectively. Adequate portions of the diets for ad libitum intake were given to the mice every other day. Body weight and food intake were monitored throughout the experiment.
Dietary lipid analysis
Total lipids from diet subsamples were extracted using the method of Folch (24), and total lipid was then converted to its methyl esters by direct trans-esterification using 1% sulphuric acid in methanol. The proportion of individual fatty acids in the diet was determined with an Agilent 6890 gas chromatograph fitted with a 30 m DB23 capillary column (J&W Scientific, Folsom, CA) with an inner diameter of 0.25 mm and 0.25 µm film thickness. Helium (25 psi) was used as a carrier gas. The initial oven temperature was programmed at 800°C, rising to 1800°C at a rate of 250°C per min, then to 220°C at a rate of 10°C per min, and then kept constant. The temperature of the injector and the flame-ionization detector was set at 2500°C, while a split ratio of 50:1 was used. A standard mixture was used to identify the fatty acid methyl esters by means of the retention times. Results were expressed as a proportion of total identified fatty acids. Butylated hydroxy-toluene (0.005% w/v, Sigma) was added to all organic solvents to prevent oxidation of the polyunsaturated fatty acids.
Plasma analyses
At weeks 0 and 3 of the intervention period, mice were fasted for 4 h, after which blood samples were obtained from the tail vain into chilled paraoxon-coated capillaries to prevent lipolysis (25) . Plasma was collected via centrifugation at 13000 rpm for 5 min for measuring plasma total cholesterol (Roche Diagnostics GmbH, Mannheim, Germany), triglycerides without free glycerol (Triglyceride GPO-Trinder, Sigma), non-esterified fatty acids (Wako Chemicals, GmbH, Neuss, Germany), glucose (Trinder 500, Sigma), and β-hydroxybutyrate (Sigma Diagnostics Inc., St. Louis, MO) by standard commercial kits, according to the manufacturers' instructions. Plasma insulin was measured by radioimmunoassay, using rat insulin standards that have 100% crossreaction with mouse and human insulin (sensitive rat insulin assay, Linco Research Inc. St. Charles, MO).
For size fractionation of lipoproteins, 50 µl of pooled plasma was injected onto a Superose 6 column (3.2×300 mm, Äkta purifier, Amersham Pharmacia Biotech, Uppsala, Sweden) and eluted at a constant flow rate of 50 µl/min with phosphate-buffered saline (pH 7.4, containing 1 mmol/l EDTA). Fractions of 50 µl were collected and assayed for total cholesterol (as described above) and triglycerides (Triglycerides GPO-PAP, Roche Diagnostics GmbH).
Liver lipid analyses
After the intervention period of 3 weeks, mice were fasted 4 h and then killed to obtain liver tissue for lipid analyses and proteomics. The liver was perfused with ice-cold PBS and weighed, and samples were snap-frozen in liquid nitrogen. Liver lipid content was analyzed by sample homogenization in phosphate-buffered saline (+/−10% wet wt/vol). Protein content was determined by a Lowry assay (26), followed by extraction of lipids using the Bligh and Dyer method (27) . The lipids were separated using high-performance thin-layer chromatography (HPTLC) on silica gel plates as described before (28) , and subsequent analysis was performed by TINA2.09 software (29) (Raytest Isotopen Meßgeräte GmbH, Straubenhardt, Germany).
Proteomics

Preparation of cytoplasm protein fraction
A piece of frozen liver (±125 mg) was added to 500 µL extraction buffer (pH 7.1) containing 50 mM Tris, 100 mM KCl, 20% glycerol, 1.4 µM pepstatin A, 1.0 mM PMSF, and the protease inhibitor cocktail Complete TM according to the manufacturer's instructions (Boehringer Mannheim). This sample was homogenized with an eppendorf homogenizer on ice for 30 s, sonicated in ice water for 15 s, and again homogenized on ice for 30 s. Thereafter the homogenate was centrifuged (Beckman TL-100) for 30 min at 55000 rpm at 4°C. The resulting supernatant was withdrawn, and the pellet was weighed and re-homogenized in the extraction buffer as outlined above. After the second centrifugation step, the supernatant was added to the first fraction and the protein content of the combined supernatant fractions was measured using the Bradford assay.
Preparation of membrane protein fraction
The pellet was weighed re-homogenized in CHAPS buffer [0.2 M KCl, 0.1 M sodium phosphate, 20% glycerol, 0.12 M CHAPS and Complete TM (Roche) according to the manufacturer's instructions] at a ratio of 2 µL buffer per mg of pellet. The sample was homogenized and sonicated as for the preparation of cytosolic proteins. Urea and DL-dithiothreitol (DTT) were added to obtain final concentrations of 9 M and 70 mM, respectively. When these additions were fully dissolved, the sample was centrifuged at 55000 rpm for 30 min at 20°C. The supernatant was carefully removed, after which 2% ampholytes 3-10 (Servalyt TM , Serva Electrophoresis, Heidelberg, Germany) were added prior to 2D electrophoresis. The protein content of the membrane protein fraction was measured using the Bradford assay (30).
Two-dimensional gel electrophoresis
For the cytoplasm protein fractions, four 2-D electrophoresis gels were run per dietary treatment, each gel representing a pool of two randomly selected animals per group. For the membrane protein fraction, two 2-D electrophoresis gels were run per treatment, each gel representing a pool of four randomly selected animals per group. BioRad immobilized pH gradient (IPG) strips (pI 5-8 for cytoplasm proteins and pI 3-10 for membrane proteins) were used for the separation of the proteins in the first dimension. Strips were rehydrated in 300 µg of protein sample at 20°C for 1 h without applied voltage on a BioRad IEF cell. After 1 h each lane was overlaid with mineral oil to prevent the strips from drying out. For another 16 h a voltage of 50 V per strip was applied, after which the strips were transferred to a clean tray and overlaid with mineral oil. The initial start up and ramping protocol were as recommended by Biorad. After 1 h the strips were removed to a tray containing fresh wicks and were overlaid with mineral oil. The run proceeded until the preset volt hours had been reached, after which the voltage was held at 500V total until the strips were ready to be transferred to the second dimension SDS-PAGE step.
SDS-PAGE
IPG strips were removed from the focusing tray and incubated in fresh equilibration buffer (6 M urea; 2% SDS; 0.375 M Tris-HCl, pH 8.8; 20% glycerol; and 130 mM DTT) for 10-15 min at room temperature before transfer to a second equilibration buffer (6 M urea; 2% SDS; 0.375 M Tris-HCl, pH 8.8; 20% glycerol; and 135 mM iodoacetamide) for 10-15 min at room temperature. The strip was then rinsed in tank buffer (24 mM Tris; 0.2 M glycine; and 0.1% SDS, pH 8.6) and applied to the top of an 18 × 18 cm gel cassette. The strip was fixed in position by overlaying with molten agarose (2% agarose in tank buffer with 2 mg/100 mL bromophenol blue). A 7.5 µL unstained BioRad precision standard was inserted in the well formed on the right of the cassette. Gels were run at 200V for 9.5 h or until the bromophenol blue had reached the bottom of the gel. After the second dimension run, the gels were placed into a fixation solution of 50% ethanol, 2% ortho-phosphoric acid, and 48% H 2 O for a minimum of 3 h. Gels were then washed for at least 1 h with two changes of deionized water, after which they were shaken in a staining solution of 34% methanol, 2% ortho-phosphoric acid, and 64% H 2 O containing 17% (NH 4 ) 2 SO 4 and 1 mg/mL Coomassie blue sprinkled on top of the staining solution.
2D-E gel comparisons
2D-electrophoresis gels were analyzed using PDQuest software (BioRad). Spots with densities that significantly differed between treatments were excised from the SDS-PAGE gels using the BioRad spot cutter. Gel plugs were directly placed into a 96-well V-bottomed plate with 100 µL of water that was removed immediately before the trypsination process. The proteins were trypsinized using the MassPrep Station (Waters, Micromass, Manchester, UK) protocol, which includes sequentially: destain steps for Coomassie Blue removal, reduction of the protein with DTT, alkylation of the protein with iodoacetamide, removal of DTT and iodoacetamide, dehydration of the gel plug, incubation with trypsin, and extraction of the peptides. Of the extracted peptides, 1 µL was applied to the target area of a 96 × 2 teflon MALDI target plate (Applied Biosystems, Warrington, UK) and allowed to dry to ~50% of the original volume. At this point, 0.5 µL of an α-cyano-4-hydroxycinnamic acid matrix solution (5 mg/ml in 70% acetonitrile/H 2 O, 0.1% TFA) was applied to the target. The samples were dried in a stream of air before Matrix-assisted laser desorption/ionization (MALDI) mass spectrometric analysis.
MALDI-TOF mass spectrometric analysis
MALDI-time of flight (TOF) mass spectrometry was performed using an Applied Biosystems Voyager-DE PRO in reflectron mode. Each spectrum was obtained using 500 shots of the appropriate laser power and, where appropriate, spectra were accumulated and filed. A macro was applied, which allowed baseline correction and de-isotoping of the peptide mass peaks. A peptide mass list of the most intense peaks was generated automatically, and this list was pasted into Matrix Science Mascot by using the MSDB database during the search. We set the following search criteria: allowance of 0 or 1 missed cleavages, trypsin as digestion enzyme, carbamidomethyl modification of cystein, methione oxidation as partial modification, and charged state as MH + .
Statistical analysis
The Mann Whitney U-test was used to determine differences in responses during the intervention period between the control group and the other treatment groups. Thus, the effects of dietary fish oil, t10,c12 CLA, elaidic acid, and fenofibrate were compared with the effect of saturated fat. All data are presented as mean ± SD. Analyses were performed using SPSS11.0 (SPSS Inc., Chicago, IL). Principal component analysis (PCA) was performed using PLS toolbox (Version 3.0, Eigenvector Research Inc., Manson, WA) working under Matlab (Version 6.5, The MathWorks Inc., Natick, MA). Analysis of correlations was done with Pearson correlation coefficients. Proteins with very low expression, specifically occurring in the fish-oil treatment, were removed from the set, as they led to many false-positive correlations between those proteins. The analysis of multiple hypotheses testing for many combinations of variables was done with the QVALUE tool (31) , running under the statistical software package R (http://www.r-project.org/). The resulting q-values estimate the probability that a correlation that is called significant is false positive. For example, a q-value of 0.05 would mean that we should expect that 5 out of 100 associations that were tested significant, are in fact false positive.
RESULTS
Physiological studies
Food intake and body weight
Both food intake and body weight remained constant in all treatment groups throughout the intervention period (data not shown).
Plasma lipids, glucose, and insulin
After the 3-week intervention period, all diets significantly lowered plasma total cholesterol levels compared with the control diet ( Table 2 ). Fish oil decreased plasma total cholesterol by 55%, t10,c12 CLA by 50%, elaidic acid by 25%, and fenofibrate by 55%, compared with the control group (all P<0.05). Analysis of the lipoprotein profiles revealed that this decrease in cholesterol could be explained by a decrease in VLDL and IDL cholesterol levels compared with the control group. t10,c12 CLA appeared to cause a slight increase in LDL cholesterol compared with the control group (Fig. 1 ).
Plasma levels of triglycerides were significantly decreased by 67% in the fish oil group and by 82% in the fenofibrate group, as compared with the control group (both P<0.05). Plasma levels of triglycerides were significantly increased by 64% in the CLA group compared with the control group (P<0.05). Plasma levels of triglycerides in the elaidic acid group did not differ significantly from the control group (Table 2) . Changes in levels of total triglycerides were due to either an increase or a decrease in the triglyceride levels of predominantly VLDL and IDL lipoprotein particles (Fig. 1) .
Fish oil and fenofibrate treatment significantly decreased the amount of free fatty acids in plasma to almost half the concentrations in the control group (both P<0.05). t10,c12 CLA and elaidic acid did not affect plasma levels of free fatty acids (Table 2) . Plasma β-hydroxybutyrate, a ketone body that is often used as an indicator of hepatic β-oxidation, was significantly increased by t10,c12 CLA, elaidic acid, and fenofibrate treatment as compared with the control group (Table 2 ; all P<0.05). The fish oil group showed a trend toward a higher plasma level of β-hydroxybutyrate, although this increase was not significant.
Plasma glucose was significantly lower in the fish oil group and in the fenofibrate group (both P<0.05). Plasma insulin levels were increased 2.8 times in t10,c12 CLA-fed animals and also slightly increased (0.25 times) in fish oil-fed animals ( Table 2 ; both P<0.05).
Liver weight and liver lipids
Consumption of fish oil led to a small but significant (P<0.05) decrease in liver weight, whereas fenofibrate treatment caused a small but significant (P<0.05) increase after 3 weeks of treatment (Table 3) . Both treatments caused a significant (P<0.05) decrease in the amount of free cholesterol, triglycerides, and cholesteryl esters in the liver cells compared with the control treatment. Consumption of t10,c12 CLA caused a twofold increase in liver weight compared with the control group (P<0.05). Liver cells contained significantly more triglycerides and less cholesteryl esters after treatment with this dietary fatty acid (Table 3) .
Proteomics
2-D gel electrophoresis and MALDI-TOF mass spectrometry
When comparing the 2-D gel electrophoresis gels, we found significant changes in the levels of 74 liver cytosolic proteins and 14 liver membrane proteins that were significantly up-or downregulated by at least one of the dietary treatments compared with the control group. Of these, we could identify 65 liver cytosolic proteins and 8 liver membrane proteins using MALDI-TOF mass spectrometry (Fig. 2) . The cytosolic proteins were categorized according to their major functions to facilitate the study of pattern changes between treatments. These classifications are arbitrary to the extent that they depend on currently recognized functions of proteins. However, clear effects could be seen on pathways that are involved with glucose and lipid metabolism, and in oxidation and aging. These pathways are also consistent with the physiological effects that were observed.
Principal component analysis
Liver cytosolic proteins
Principal component analysis of the log-transformed spot density values revealed that more than 47% of all variance in the dataset was accounted for by the first principal component (PC1) and nearly 21% of variance in the dataset was accounted for by the second principal component (PC2; Fig. 3, upper panel) . The largest treatment effect on the first principal component (i.e., the largest distance between the spots representing the saturated fat control group and the spots representing a dietary intervention group on the x-axis) was produced by fish oil. When considering the second principal component, fenofibrate treatment initiated a specific treatment effect, whereas all other treatments were situated much closer to the saturated fat control group. Treatment with elaidic acid produced the least treatment effect in relation to the saturated fat control group, both for PC1 and PC2. Table 4A summarizes the cytosolic proteins that provide the largest contribution to the dietary treatment effects in the principal component analysis.
Liver membrane proteins
Principal component analysis of the log-transformed spot density values revealed that more than 40% of all variance was accounted for by PC1 and more than 30% of variance was accounted for by PC2 (Fig. 3, lower panel) . The largest treatment effect was produced by elaidic acid, both on PC1 and PC2. The proteins that provided the largest contributions to the dietary treatment effects in PCA are outlined in Table 4B .
Pair-wise correlation analysis
In addition to PCA, we performed a pair-wise correlation analysis over the different treatments, including the physiological data on plasma lipid, glucose and insulin levels, liver lipids (Tables 2  and 3) , as well as the data on protein levels. Such an analysis shows which parameters vary in a similar way throughout the different treatments. Figure 4 shows a network of pair-wise interactions with a Pearson correlation higher than 0.8, a relating P-value of 0.0053 or lower, and a relating q-value of 0.026 or lower, prepared using the software tool Cytoscape (32) .
DISCUSSION
This study has been unique in two ways. First it compared three important dietary fatty acids known to regulate lipid, and possibly glucose metabolism, in a single well-validated animal model for lipid metabolism and atherosclerosis. Second, it combined physiological data on plasma and liver levels with a proteomic study of liver proteins. Such a combined approach allowed us to identify pathways and proteins that may underlie the changes in lipid and glucose metabolism under these dietary regimes. Conclusions from the results can first be derived by considering individual dietary treatments.
Fenofibrate and fish oil
In our mouse model, we used fenofibrate as a positive control for changes in fatty acid catabolism, as this drug represents a validated agonist of PPARα (23) . Fenofibrate indeed changed proteins involved in fatty acid oxidation (see Fig. 2 and Table 4A ), lowered plasma and liver triglyceride levels, reduced plasma levels of free fatty acids, and increased β-hydroxybutyrate levels.
The modification of plasma lipoprotein metabolism by omega 3 fatty acids represents a major anti-atherogenic mechanism of action (33) . Dietary polyunsaturated fatty acids (PUFA) inhibit lipogenesis by suppressing the expression of a number of hepatic enzymes involved in glucose metabolism and fatty acid biosynthesis (34-38) through a reduced expression of sterol regulatory element binding protein-1 (SREBP-1). At the same time, PUFA induce genes encoding proteins involved in fatty acid oxidation and ketogenesis by activation of PPARα (10, 34, 39) . The latter mechanism is shared by both omega-3 fatty acids and the hypotriglyceridemic drug fenofibrate (23) . Indeed, in this study both fish oil and fenofibrate exerted similar effects at a physiological level. Both treatments significantly lowered plasma cholesterol and triglyceride concentrations as compared with a saturated fat control diet, which coincided with a significant parallel reduction in levels of cholesteryl esters, free cholesterol, and triglycerides in the liver. These effects are likely caused by an enhanced fatty acid oxidation rate, as indicated by the level of β-hydroxybutyrate in plasma.
Proteome analyses of the mouse liver samples also revealed an increase in the rate of fatty acid oxidation, as levels of catalase and long-chain acyl-CoA thioester hydrolase (both the cytosolic and the mitochondrial form) were significantly increased upon treatment with fish oil and fenofibrate. Till now, long-chain acyl-CoA thioester hydrolase has not been linked to specific dietary fatty acid treatments. Acyl-CoA thioesterases hydrolyze CoA esters of various lengths to free fatty acids and CoA-SH, and they are likely to play important roles in maintaining appropriate CoA-SH levels during periods of increased β-oxidation and fatty acid overload (40) . The existence of selective acyl-CoA thioesterases could provide important control points in the oxidation of many peroxisomal substrates, and they may regulate intracellular levels of CoA esters and CoA-SH. To date, several thioesterase isoforms have been identified in peroxisomes, cytoplasm, and mitochondria, where they are thought to have distinct functions in lipid metabolism (40) . Treatment of mice with the peroxisome proliferators clofibrate also induced levels of long-chain cytosolic, mitochondrial, and peroxisomal acyl-CoA thioester activity in the liver in a previous study, although the cytosolic form was most strongly induced (41) .
The lowering in liver lipids in the fish oil and fenofibrate groups matched a large reduction of the level of adipophilin in the liver on the 2-D electrophoresis gels (Fig. 2) . Adipophilin is a protein associated with lipid storage droplets, which are dynamic structures that function as storage deposits for triglycerides and cholesterol esters (42) .
Although fish oil and fenofibrate are believed to share common modes of action, our PCA analysis did show diverse treatment effects of both dietary interventions. The proteins responsible for the treatment effect of fish oil were involved in a range of metabolic functions (Table 4A) , whereas the list of proteins responsible for the treatment effect of fenofibrate was dominated by those involved in β-oxidation of fatty acids. This indicates that fish oil, unlike fenofibrate, triggers a more diverse range of mechanisms that could affect the physiological outcome.
t10,c12 CLA
Accumulating evidence indicates that CLA, in particular the t10,c12 isomer, may affect lipoprotein metabolism. We observed a significant increase in hepatic triglyceride levels and a twofold increase in liver weight upon treatment with t10,c12 CLA, and these findings were mirrored by a significant increase in hepatic levels of adipophilin. This protein also showed a high loading toward the treatment effect of t10,c12 CLA in the PCA analysis. Increased expression of adipophilin has been associated with liver steatosis before (43) , and recent attention has focused on the excessive accumulation of triglycerides (TG) in the liver, or liver steatosis, as part of the syndrome that involves visceral obesity and dyslipidemia, insulin resistance, and type 2 diabetes mellitus (44) . CLA-mediated liver steatosis has been observed in other studies in different strains of mice (45-53) but not in other animals. Several lines of evidence indicate that hepatic TG accumulation is also a causative factor involved in hepatic insulin resistance (44) , and indeed, hyperinsulinemia in t10,c12 CLA-fed mice has been observed in several studies (50, 52, 54, 55) as well as in our study, as evidenced by an almost threefold increase in plasma insulin levels ( Table 2 ). In a hyperinsulinemic state, a shift in fuel usage from carbohydrates to fat usually occurs, leading to an increase in the rate of β-oxidation of fatty acids as well as an increase in ketogenesis. Indeed, we found a significant increase in levels of plasma ketone bodies, as well as increased protein levels of carnitine palmitoyltransferase, catalase, and long-chain acyl-CoA thioester hydrolase upon treatment with t10,c12 CLA. Higher activity and mRNA expression of various mitochondrial and peroxisomal fatty acid oxidation enzymes upon treatment with a CLA mixture has been found previously in C57Bl/6J mice (50).
The increased ratio of triglycerides to cholesteryl esters in the liver upon feeding t10,c12 CLA was clearly reflected in the lipid composition of the lipoproteins. The converse effect of t10,c12 CLA on plasma triglycerides and cholesterol suggests independent mechanisms by which CLA affects these levels. Furthermore, the effect of t10,c12 CLA on plasma triglyceride levels in mice depends on the mouse strain used. Some studies report that CLA is effective in decreasing plasma triglyceride levels (48, 51, 56), others report no effect on plasma triglyceride levels (50, 55), whereas we found a dramatic increase in plasma triglycerides. The decrease in plasma triglyceride levels in previous studies has been attributed to an up-regulation of the LDL receptor. It appears therefore, that the overall effect of CLA on plasma triglyceride levels is determined by two opposite actions of CLA: overproduction of VLDL and up-regulation of LDL receptors. In our APOE3*Leiden model with impaired clearance, the former action apparently dominated and resulted in hypertriglyceridaemia.
Elaidic acid
Although studies investigating the mechanism of action of trans fatty acids are limited, several controlled metabolic studies have shown the unfavorable effects of trans fatty acids on lipoprotein metabolism and other biomarkers for coronary heart disease. Trans fat in the diet has been shown to increase levels of LDL cholesterol and triglycerides (1) , and a high intake of trans fat has been associated with the development of insulin resistance and type 2 diabetes in humans (15, 57) . However, in our mouse model, dietary elaidic acid decreased plasma levels of cholesterol and had no effect on plasma levels of triglycerides, glucose, or insulin. However, this comparison was made against a saturated fat control diet, which might have masked the true negative effects of the elaidic acid.
Trans fatty acids are incorporated into membrane phospholipids and may therefore alter the packaging of the phospholipid and possibly influence the physical properties of the membrane or the activities of membrane-associated enzymes (58) . We observed a very specific effect of elaidic acid treatment on protein levels in liver membranes revealed by principal component analysis. The proteins that provided the largest positive contribution to the differences between the elaidic acid treatment and the other dietary treatments were aldehyde dehydrogenase and CTP synthase. Levels of these proteins were up-regulated by more than 200% by elaidic acid. CTP synthase has been implicated in the regulation of phospholipid biosynthesis, at least in Saccharomyces cerevisiae (59) .
Comparative analysis of all treatments
Principal component analysis was used to analyze the effects of the various treatments on the protein levels in the complete dataset. This approach visualizes the extent to which different treatments have similar, or very different, effects on protein expression. Clearly, fish oil triggered a different treatment effect on cytosolic protein expression compared with all other treatments. Elaidic acid showed the strongest treatment effect on the liver membrane proteins studied.
The pair-wise correlation analysis revealed many associations, resulting in clustering of proteins that are related to each other (Fig. 4) . Some of these relations have been described before and are therefore consistent with previous studies, adding validity to the novel associations revealed by our study of the APOE*3-Leiden mouse. For example, the associations within the cluster containing plasma and liver triglycerides, plasma glucose, plasma free fatty acids, and protein levels of hepatic fructokinase and fructose 1,6 bisphosphatase are all related to dyslipidaemia and glucose intolerance, two important conditions related to the metabolic syndrome or Syndrome X. It is striking that this cluster is observed already in a dataset with relatively mild perturbations and at equal body weights but with clearly different liver weight and composition. The position of sepiapterin reductase in the middle of this cluster is unexpected. However, sepiapterin reductase is involved in the biosynthesis of tetrahydrobiopterin, an essential co-factor for eNOS activity (60) , and may therefore play a role in the relationship between dyslipidaemia, insulin resistance and endothelial dysfunction (61, 62) .
A second recognized cluster is that of the proteins catalase and two different forms of long-chain acyl CoA thioester hydrolases, which are related to the β-oxidation of fatty acids. The addition of cysteine sulfinic acid decarboxylase to this cluster has, however, not been described before. Cysteine sulfinic acid decarboxylase is a rate-limiting enzyme for taurine biosynthesis, and taurine can be tissue-protective in many models of oxidant-induced injury (63) . Therefore, cysteine sulfinic acid decarboxylase, like catalase, might be involved in the protection of cells against oxidative stress generated by fatty acid oxidation.
Proteomics of diet-induced changes in the liver of APOE*3-Leiden mice revealed a wide array of proteins that were affected by the various dietary interventions. Our approach visualized the 500-800 most abundant proteins from a liver cell on a 2-D electrophoresis gel, and this provided a detailed overview of novel and recognized alterations in lipid degradation and glycolysis pathways, reflecting changes in lipoprotein and glucose metabolism upon dietary treatment. We found, for example, that the consumption of specific dietary fatty acids induced a differential expression of long-chain acyl-CoA thioester hydrolase protein (as an indicator of β-oxidation) and adipophilin (as an indicator of liver lipid content). Statistical analysis of our results revealed many associations, some of which are well known (like the metabolic syndrome), whereas others will be the basis of intriguing new leads for further studies.
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